Here's a brief information about Z-Mapp, the experimental drug for Ebola virus, released by the manufacturer of the drug, Mapp Biopharmaceutical. The information is in PDF format but I have copied and pasted it below for the benefit of those using devices that can't view PDF files. However, the PDF format is attached.

ZMappTM Information Sheet

ZMapp is the result of a collaboration between Mapp Biopharmaceutical, Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimized cocktail combining the best components of MB‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available.

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

very informative. Clinical trials nko